Stock News

Bluecrest Capital Management LTD Boosted By $797,941 Its Neurocrine Biosciences (NBIX) Stake; RANDSTAD HOLDINGS NV ORDINARY SHARES (RANJF) Shorts Down By 4.95%

RANDSTAD HOLDINGS NV ORDINARY SHARES (OTCMKTS:RANJF) had a decrease of 4.95% in short interest. RANJF’s SI was 205,600 shares in February as released by FINRA. Its down 4.95% from 216,300 shares previously. The SI to RANDSTAD HOLDINGS NV ORDINARY SHARES’s float is 0.11%. It closed at $72.85 lastly. It is up 0.00% since February 23, 2017 and is . It has underperformed by 16.70% the S&P500.

Bluecrest Capital Management Ltd increased Neurocrine Biosciences Inc (NBIX) stake by 108.11% reported in 2017Q3 SEC filing. Bluecrest Capital Management Ltd acquired 13,081 shares as Neurocrine Biosciences Inc (NBIX)’s stock rose 19.84%. The Bluecrest Capital Management Ltd holds 25,181 shares with $1.54M value, up from 12,100 last quarter. Neurocrine Biosciences Inc now has $7.48 billion valuation. The stock decreased 1.90% or $1.62 during the last trading session, reaching $83.8. About 272,190 shares traded. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has risen 12.51% since February 23, 2017 and is uptrending. It has underperformed by 4.19% the S&P500.

Among 13 analysts covering Neurocrine Biosci (NASDAQ:NBIX), 13 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Neurocrine Biosci had 49 analyst reports since August 18, 2015 according to SRatingsIntel. The rating was initiated by Oppenheimer with “Perform” on Tuesday, November 22. Leerink Swann maintained the stock with “Buy” rating in Tuesday, February 20 report. The rating was maintained by BMO Capital Markets on Friday, October 20 with “Buy”. Oppenheimer maintained it with “Buy” rating and $7000 target in Friday, August 4 report. Robert W. Baird maintained the shares of NBIX in report on Monday, October 23 with “Buy” rating. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has “Buy” rating given on Tuesday, July 11 by H.C. Wainwright. On Tuesday, October 3 the stock rating was maintained by BMO Capital Markets with “Buy”. Robert W. Baird maintained Neurocrine Biosciences, Inc. (NASDAQ:NBIX) rating on Thursday, September 21. Robert W. Baird has “Buy” rating and $66.0 target. The company was initiated on Thursday, April 7 by BMO Capital Markets. Leerink Swann maintained Neurocrine Biosciences, Inc. (NASDAQ:NBIX) rating on Thursday, November 2. Leerink Swann has “Outperform” rating and $83 target.

Since September 5, 2017, it had 0 insider buys, and 25 insider sales for $27.00 million activity. The insider Gano Kyle sold $169,914. $295,820 worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares were sold by GORMAN KEVIN CHARLES. On Wednesday, January 24 RASTETTER WILLIAM H sold $855,000 worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) or 9,500 shares. $217,341 worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) was sold by OBrien Christopher Flint on Monday, February 5. Bozigian Haig P. had sold 2,262 shares worth $187,977 on Monday, February 5. $227,494 worth of stock was sold by Lippoldt Darin on Monday, February 5. BENEVICH ERIC had sold 820 shares worth $68,174 on Monday, February 5.

Investors sentiment increased to 1.66 in Q3 2017. Its up 0.41, from 1.25 in 2017Q2. It is positive, as 22 investors sold NBIX shares while 45 reduced holdings. 32 funds opened positions while 79 raised stakes. 92.69 million shares or 0.83% more from 91.92 million shares in 2017Q2 were reported. Dekabank Deutsche Girozentrale, a Germany-based fund reported 112,500 shares. California Public Employees Retirement Systems reported 0.02% stake. First Republic Management Inc accumulated 23,692 shares. Bluecrest Management Ltd holds 0.06% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) or 25,181 shares. Aperio Group Inc Ltd Limited Liability Company holds 0.01% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) or 21,912 shares. The New York-based Tiaa Cref Invest Mgmt Limited Co has invested 0.01% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Orbimed Advsr has invested 0.17% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Gam Hldgs Ag holds 0.31% or 119,200 shares. Pnc Services Gp holds 0% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) or 2,165 shares. Rmb Cap Mgmt Limited owns 63,052 shares. Rothschild Asset holds 0.03% or 37,745 shares. Tocqueville Asset Mgmt Ltd Partnership holds 0.01% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) or 17,525 shares. Federated Investors Pa owns 124,654 shares. Weiss Asset Management Ltd Partnership reported 3,507 shares or 0.02% of all its holdings. Grandfield Dodd Ltd Liability invested 0.05% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

Leave a Reply

Your email address will not be published. Required fields are marked *